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In Brief
A systematic proteogenomic analysis of
colon cancer reveals vulnerabilities of
potential clinical value inaccessible from
genomic assessment alone.
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We performed the first proteogenomic study on
a prospectively collected colon cancer cohort.
Comparative proteomic and phosphoproteomic
analysis of paired tumor and normal adjacent tis-
sues produced a catalog of colon cancer-associ-
ated proteins and phosphosites, including known
and putative new biomarkers, drug targets, and
cancer/testis antigens. Proteogenomic integration
not only prioritized genomically inferred targets,
such as copy-number drivers and mutation-derived
neoantigens, but also yielded novel findings. Phos-
phoproteomics data associated Rb phosphoryla-
tion with increased proliferation and decreased
apoptosis in colon cancer, which explains why
this classical tumor suppressor is amplified in
colon tumors and suggests a rationale for targeting
Rb phosphorylation in colon cancer. Proteomics
identified an association between decreased CD8
T cell infiltration and increased glycolysis in micro-
satellite instability-high (MSI-H) tumors, suggesting
glycolysis as a potential target to overcome the
resistance of MSI-H tumors to immune check-
point blockade. Proteogenomics presents newThis is an open access article under the CC BY-Navenues for biological discoveries and therapeutic
development.INTRODUCTION
Colorectal cancer (CRC) is the thirdmost common cancer world-
wide and the fourth leading cause of cancer-related deaths
(Arnold et al., 2017). Recent studies of the genomic, transcrip-
tomic, and proteomic landscapes of human CRC have identified
many genomic alterations and have revealed extensive molecu-
lar heterogeneity of the disease (Cancer Genome Atlas Network,
2012; Guinney et al., 2015; Zhang et al., 2014). However, the
rapidly accumulating omics data have yet to bring novel bio-
markers and drug targets to the clinic.
Global proteomic differences between tumor and normal tis-
sues, which are critical for cancer biomarker discovery, have
not been systematically characterized in large tumor cohorts.
Signaling proteins and pathways are often attractive therapeutic
targets for cancer treatment, yet global phosphoproteomic ana-
lyses on human CRC are lacking. Recent advances in cancer
immunotherapy underscore the critical need for biomarkers to
predict response to immune checkpoint inhibition and to select
neoantigens for personalized vaccine development (Sharma
et al., 2017). Proteogenomics can provide fresh approaches to
these needs. Here, we describe a proteogenomic study from
the Clinical Proteomic Tumor Analysis Consortium (CPTAC) onCell 177, 1035–1049, May 2, 2019 ª 2019 Elsevier Inc. 1035
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Schematic Overview of the Study
(A) Samples and omics platforms for data generation.
(B) Therapeutic hypothesis generation through proteogenomic integration. The colors represent data generated from different omics platforms as indicated by
the same colors in (A).
See also Figure S1 and Table S1.a prospectively collected colon cancer cohort to systematically
identify new therapeutic opportunities.
RESULTS
Proteogenomic Profiling
We prospectively collected tumor specimens, matched normal
adjacent tissues (NATs), and blood samples from 110 colon can-
cer patients. We performed whole-exome sequencing (WXS),
copy-number array, RNA sequencing (RNA-seq), microRNA
sequencing (miRNA-seq), and label-free shotgun proteomic
analyses on the tumor samples, similar to our previous study
(Zhang et al., 2014). To characterize the proteomes in cancer
and normal states, we further performed isobaric tandem mass
tag (TMT) labeling-based global and phosphoproteomic analysis
on both tumors and NATs (Figure 1A). Table S1 summarizes the
clinical and pathological characteristics of the tumors.
Although this study includes only colon tumors, rather thanboth
colon and rectal tumors in The Cancer Genome Atlas (TCGA)
cohort (Zhang et al., 2014), the averagemRNAprofileswere highly
correlated between the two cohorts (Pearson’s r = 0.92) as were
the average label-free protein profiles (Pearson’s r = 0.96), and
these correlations were higher than those between different can-
cer types or between colon tumors and cell lines (Figures S1A–1036 Cell 177, 1035–1049, May 2, 2019S1G). Principal component analysis clearly separated the tumors
and NATs based on the TMT global or phosphoproteomics data,
and no batch effect was observed between the TMT plexes (Fig-
ures S1H and S1I). Correlation of proteomics data between the
label-free and TMT platforms was higher than for either with
RNA-seq data (Figures S1J–S1L). Label-free proteomics data
from colon tumors outperformed RNA-seq data for gene function
prediction, and TMT data further outperformed both (Figures
S1M–S1O). These results affirm the consistency of the two prote-
omic platforms and the added value of proteomics for assessing
gene functions. Based on the comprehensive molecular profiling
datasets, we performed integrative proteogenomic data ana-
lyses, focusing on using global and phosphoproteomics data to
improve the interpretation of genomics data and to reveal new
therapeutic opportunities (Figure 1B).
Somatic Mutations and Their Proteomic Consequences
WXS analysis of 106 tumor specimens and matched blood sam-
ples identified 64,010 somatic single nucleotide variants (SNVs)
and 7,691 somatic insertions/deletions (INDELs) (Figures S2A
and S2B). A focused analysis of microsatellites further identified
6,186 somatic microsatellite INDELs (MS INDELs) (Figure S2C;
Table S2). In total, we identified 56,592 unique somatic protein
altering events (Table S3).
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The number of MS INDELs showed a clear bimodal distribu-
tion, which allowed us to separate the samples into a microsat-
ellite instability-high (MSI-H) group (n = 24) and a microsatellite
stable (MSS) group (n = 82, Figure S2D). For the 85 samples
with PCR-based MSI testing results, WXS-based assignment
agreed completely with PCR assignment (Table S2). MSI-H
tumors showed a distinct mutational spectrumwith an increased
proportion of A > G/T > C transitions and decreased G > C/C > G
transversions compared toMSS tumors (Figure S2E). TheMSI-H
group was enriched with mutations in the mismatch repair
pathway and in the POLE and BRAF genes (Figure S2F).
To identify significantly mutated genes, we grouped the MSI-
H and the one hypermutated MSS sample with a POLE muta-
tion into a hypermutated group; the remaining samples formed
a non-hypermutated group (Figure S2D). In the non-hypermu-
tated group, we identified eight significantly mutated genes
(Figure 2A), which all were reported in the TCGA study (Cancer
Genome Atlas Network, 2012). In the hypermutated group, we
identified nine significantly mutated genes (Figure 2B), six of
which were not reported in the TCGA study. Four genes newly
identified in this study, namely CASP5, RNF43, LTN1, and
BMPR2, were mutated in more than 50% of the hypermutated
samples.
The TMT data on matched tumors and NATs allowed us to
investigate the proteomic consequences of somatic mutations.
Some protein changes could be predicted from the mutations,
such as the stop-gain and frameshift mutations in APC, which
result in nonsense-mediated mRNA decay or truncated proteins.
As expected, tumors with these mutations had reduced abun-
dance of phosphosite APC-T2451, which is located downstream
of the mutations (Figure 2C). Similarly, tumor samples bearing
frameshift mutations in TGFBR2 showed reduced abundance
of phosphosite TGFBR2-S553 (Figure 2D).
Some protein changes were difficult to predict based on the
mutations. For example, phosphorylation of TP53-S315 was
increased in tumors over matched NATs (p = 0.001, paired
t test). Three tumors with more than 10-fold increase of TP53-
S315 phosphorylation all had an R273 mutation (Figure 2E).
We reviewed TP53-S315 phosphorylation data from the CPTAC
breast (Mertins et al., 2016) and ovarian cancer (Zhang et al.,
2016) studies and found TP53-S315 phosphorylation in tumors
with R273 mutations was 3.4- to 83-fold above the medians of
those cohorts, strengthening the association between these
hotspot mutations and increased TP53-S315 phosphorylation.
The high mobility group (HMG) transcription factor SOX9 was
recurrently mutated in this cohort, including six stop-gain muta-Figure 2. Somatic Mutations and Their Proteomic Consequences
(A and B) Significantly mutated genes in non-hypermutated (A) and hypermutated
reported in the TCGA study are shown in bold font.
(C–F) Somatic mutations versus protein/phosphosite abundance change for APC
plot visualizes all protein altering somatic mutations detected in this cohort. The si
and the color represents a specific type of mutation as indicated in the figure le
indicated by a triangle. The bottom panel co-visualizes the mutation and protein
colored box denotes the existence of a specific type of mutation as indicated in the
more than one type of mutation, only one type is shown in the following order of
ymous SNV. In the waterfall plot, each bar represents the protein or phosphosite
patient. Red and green bars represent over- and under-expression in tumor, res
See also Figure S2 and Tables S2 and S3.
1038 Cell 177, 1035–1049, May 2, 2019tions, eight frameshift mutations, and five nonsynonymous
SNVs. According to the ‘‘20/20 rule’’ that classifies genes with
more than 20% truncatingmutations as tumor suppressor genes
(Vogelstein et al., 2013), SOX9 should be classified as a tumor
suppressor. However, SOX9 protein was significantly overex-
pressed in tumor samples compared to matched NATs (p =
1.02 3 1010, paired t test, Figure 2F), which argues against a
tumor suppressor assignment. Even in tumors with the trun-
cating mutations, despite the small number of samples, we still
observed statistically significant overexpression of SOX9 (p =
0.04, paired t test, Figure 2F). Interestingly, most of the trun-
cating mutations occurred downstream of the HMG-box domain
and upstream of the evolutionally conserved ubiquitin-target site
K398 (Figure 2F), which is responsible for 26S proteasome
dependent degradation of SOX9 (Akiyama et al., 2005). Thus,
removal of the K398 ubiquitination site through the truncating
mutations may stabilize SOX9 protein and increase protein
abundance. Consistent with these data, functional assays sup-
port an oncogenic rather than tumor suppressor role of SOX9
in primary CRC cells (Matheu et al., 2012).
Taken together, our somatic mutation analyses identified
new significantly mutated genes among MSI-H tumors,
and the proteomics data revealed unexpected functional
complexity that could not have been predicted from mutation
data alone.
Proteomics Data Prioritize Somatic Copy-Number
Alterations
We performed somatic copy-number alteration (SCNA) analyses
with WXS data and Illumina SNP array data, but the SNP array
data showed low dynamic range. Hence, we only report SCNAs
identified fromWXS analysis. We identified very similar arm level
SCNAs to the TCGA cohort, including amplifications of 1q, 7p
and q, 8p and q, 13q, and 20p and q, and deletions of 1p, 14q,
15q, 17p and q, 18p and q, and 22q (Figure 3A). Focal level
SCNAs (Figure 3B) did not completely agree with those reported
in the TCGA study, which may reflect cohort and/or platform dif-
ferences. Nonetheless, most focal SCNAs previously reported
were found in our cohort. Cytobands in chromosome 20
(20p12.1, 20q13.12, 20q13.13) and chromosome 18 (18q21.2)
contained the most frequently amplified and deleted focal re-
gions, respectively (Figure 3B).
Next, we examined the correlations of SCNA with mRNA and
protein abundance. While cis-effects of SCNAs on mRNA
abundance were similar to our previous study (Zhang et al.,
2014), cis-effects on protein abundance were stronger(B) samples. Mutation frequency is shown at the top for each gene. Genes not
(C), TGFBR2 (D), TP53 (E), and SOX9 (F). For each gene, the top panel lollipop
ze of a lollipop represents the number of samples with correspondingmutation,
gend. The location of the post-translational modification (PTM) of interest is
or phosphosite abundance data for individual samples. For mutation data, a
figure legend. Gray boxes indicate data are not available. If a given sample has
priority: stop-gain, frameshift-INDEL, non-frameshift INDEL, and non-synon-
abundance change between tumor and matched normal adjacent tissue for a
pectively. White space in the waterfall plots indicates missing values.
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Figure 3. Somatic Copy-Number Alteration Analysis
(A) Arm-level somatic copy-number alteration (SCNA) events. Red denotes amplification and blue denotes deletion.
(B) Focal-level SCNA events. Focal peaks with significant copy-number gains (red) and losses (blue) (GISTIC2 Q-values <0.25) are shown. The top ten amplified
and deleted cytobands are labeled, with the proportions of amplified or deleted samples shown in the parentheses. Representative genes encoded from these
focal peaks are highlighted in approximate positions across the genome.
(C) Effects of copy-number alternations onmRNA and protein abundance. The upper heatmap shows the abundance of significant copy-number correlation with
mRNA (left) and protein (right). Significant positive and negative correlations (adj. p < 0.01, Spearman’s correlation coefficient) are indicated by red and blue,
respectively. Genes are ordered by chromosome locations on both x- and y-axes. The bottom shows the frequency of significant correlations. Gray bars
represent copy-number correlation to mRNA (left) and protein (right), and black bars represent copy-number correlation to both mRNA and protein.
(D) Strategy for prioritizing genes in focal alteration peaks.
(E) Most enriched KEGG pathways and Gene Ontology (GO) biological processes (BP) for genomic drivers inferred in this study.
(F) Six deleted genes involved in endocytosis. Violin plots compare protein expression in tumor and normal adjacent tissue for each gene.
See also Table S4.(Figure 3C), reflecting the greater quantitative precision of the
TMT platform compared to the previous label-free analysis. We
also confirmed previously reported trans-acting SCNA hotspots
on chromosomes 20q, 18, 16, 13, and 7 and identified a new
hotspot on chromosome 14 (Figure 3C).
Previously, we showed that correlated copy number, mRNA,
and protein levels can prioritize copy-number drivers in focal
alteration regions. Here, we found that only 59% of such priori-
tized amplification or deletion drivers showed expected pro-
tein-level effects in tumor versus NAT comparisons (Figure 3D).
Thus, data from NATs can substantially refine candidate driver
lists (Table S4). The final prioritized list included the previously re-
ported 20q amplification drivers HNF4A and TOMM34. We alsoidentified the well-known tumor suppressor SMAD4 in the 18p
focal deletion region.
To better understand the genomic drivers inferred in this
study, including the 17 significantly mutated genes and the
90 prioritized SCNA genes, we performed enrichment analysis.
Not surprisingly, significantly enriched terms included colorectal
cancer, cell proliferation, cell death, and Hippo signaling
pathway (Figure 3E). Enrichment for endosome organization
and endocytosis, including six genes located in different focal
deletion regions across the genome (Figure 3F), indicated that
multiple deletion events converge to repress the endocytosis
pathway, which may allow tumors to gain self-sufficiency in
growth signals (Mosesson et al., 2008).Cell 177, 1035–1049, May 2, 2019 1039
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Figure 4. Rb Phosphorylation as a Driver and Therapeutic Target in Colon Cancer
(A–C) RB1 Copy-number alteration (CNA) (A), protein log2 fold change (FC) from normal (B), and phosphorylation log2 fold change from normal (C). Samples are
ordered by increasing average phosphorylation abundance.
(D and E) Correlations of Rb protein abundance change (D) and average Rb phosphorylation change (E) with estimated E2F1 activity change.
(F–H) Correlation of average Rb phosphorylation change with estimated CDK2 activity change (F), H3.1 phosphorylation change (G), and protein level changes of
apoptotic proteins (H).
(I) A model depicting the multi-level regulation of RB1 in colon cancer, highlighting Rb phosphorylation as a driver and therapeutic target in colon cancer.
The p values in (D)–(H) were calculated by Pearson’s correlation test. See also Figure S3.Rb Phosphorylation as a Driver and Therapeutic Target
in Colon Cancer
One of the recurrently amplified genes in this cohort was the
retinoblastoma (RB1) gene (Figure 4A). Consistently, the RB1
protein (Rb) was overexpressed in tumors compared to NATs
(p = 2.10 3 1015, paired t test, Figure 4B). RB1 was the first
tumor suppressor gene identified, and its amplification and over-
expression in colon cancer contradict its frequent mutation and
deletion in other cancers (Figure S3).
As a tumor-suppressor, Rb prevents cell proliferation by inhib-
iting E2F transcription factors, but this inhibition is abolished by
Rb phosphorylation (Rubin, 2013). Phosphoproteomics quanti-
fied six Rb phosphorylation sites in at least 50% of all samples,
including four sites (i.e., T373, S807, S811, and T826) that regu-
late E2F binding (Knudsen and Wang, 1997; Rubin, 2013). The
average abundance of the four sites was higher in colon tumors
than in NATs (p < 2.2 3 1016, paired t test) (Figure 4C). More-
over, the average tumor versus NAT change for phospho-Rb
was 1.84-fold, which was significantly higher (p = 0.01, Wilcoxon
signed-rank test) than the 1.58-fold average change for total Rb1040 Cell 177, 1035–1049, May 2, 2019measured from global proteomics. Thus, tumor samples had not
only higher total Rb, but also a higher proportion of phospho-Rb
within the total Rb pool.
Predicted E2F1 activity changes between tumors and NATs
(STAR Methods) were positively correlated with both total Rb
change (Pearson’s r = 0.40, p = 5.13 105, Figure 4D) and phos-
pho-Rb change (Pearson’s r = 0.30, p = 3.5 3 103, Figure 4E).
Because un-phosphorylated Rb inhibits E2F1 activity, the signif-
icant positive correlation between total Rb and E2F1 activity sug-
gests that the increase of total Rb in tumors is attributable to
phospho-Rb, rather than un-phosphorylated Rb. The positive
correlation between E2F1 activity and phospho-Rb may reflect
a positive feedback loop (Sherr and McCormick, 2002), in which
E2F1 transcriptionally upregulates cyclin E, which activates
CDK2, thereby phosphorylating Rb and relieving E2F1 inhibition
of cell proliferation. Indeed, phospho-Rb change showed the
highest correlation with the predicted activity change of CDK2
(r = 0.47, p = 1.83 106, Figure 4F) compared to all other kinases
(STAR Methods). Further, phospho-Rb change was significantly
correlated with the phosphorylation change of histone H3.1, a
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marker for cell proliferation (Pearson’s r = 0.49, p = 2.6 3 104,
Figure 4G). Therefore, our data showed that increased Rb phos-
phorylation, instead of RB1 mutation or deletion, drives colon
cancer proliferation. However, it remains puzzling why RB1 is
recurrently amplified in colon tumors, because post-translational
downregulation of the inhibitory activity of this overexpressed
protein seems mechanistically inefficient. Further analysis
showed that Rb phosphorylation change in colon tumors was
negatively correlated with the apoptosis hallmark gene set
(STARMethods, Pearson’s r =0.28, p = 5.33 103, Figure 4H),
which primarily comprises pro-apoptotic genes (Liberzon et al.,
2015). Thus, phospho-Rb appears to have an antiapoptotic role.
Together, proteogenomic data integration suggests that Rb
phosphorylation regulates both proliferation and apoptosis to
drive colon cancer development (Figure 4I). This insight reveals
a previously unexploited opportunity to target Rb phosphoryla-
tion in colon cancer through CDK2 inhibition, which is not
possible for cancers driven by RB1 mutation or deletion.
Colon Cancer-Associated Proteomic Events and
Potential Clinical Utilities
TMT global proteomic analysis of the 96 tumor and NAT pairs
identified a total of 8,067 proteins. Among the 6,422 proteins
that were quantified in at least 50% of the samples (i.e., quantifi-
able proteins), 2,217 (35%) were significantly increased and
2,527 (39%) were significantly decreased in tumors compared
to paired NATs (adjusted [adj.] p < 0.01, Wilcoxon signed-rank
test, Figure 5A). Of these, 31 increased and 417 decreased pro-
teins had amore than 2-fold abundance change. The 417proteins
elevated in NATs were significantly enriched in muscle-related
functions (Figure 5B), as expected from normal colon histology,
which includes defined muscular structures that are typically
absent in tumors. We focused our analysis on the 31 proteins
elevated by more than 2-fold in tumors, which we defined as
colon cancer-associated proteins (Table S5).
Figure 5C depicts the distributions of pairwise tumor-NAT
differences for the 31 cancer-associated proteins. Most showed
highly homogeneous differential expression across the 96Figure 5. Colon Cancer-Associated Proteomic Events
(A) Volcano plot indicating proteins overexpressed in tumors or normal adjacent t
and blue further require more than 2-fold change); other genes are colored in gra
(B) Gene Ontology biological processes enriched for the 417 proteins downreg
process related genes and the 417 proteins.
(C) Log2-fold change between tumor and matched NATs is shown for the 31 can
(D) Tumor-cell specific immunohistochemistry (IHC) staining scores defined by th
(E) Overlap with plasma proteins, secreted proteins, transmembrane proteins, an
(F) Volcano plot indicating phosphosites overexpressed in tumors or NATs. Colo
(G) Correlation between tumor-normal protein and phosphorylation site abunda
indicates the diagonal line. Red points indicate the phosphorylation sites with >2-
lower protein abundance in tumors than in NATs.
(H) Overlap of proteins containing cancer-associated phosphorylation sites (phosp
Cancer Gene Census (CGC).
(I) Cancer-associated kinases identified by increased phosphorylation of a kno
phosphosite set enrichment analysis based on known kinase-target site relationsh
the existence of an FDA-approved drug or a drug undergoing clinical trials targe
(J) The number of proteomics-supported neoantigens identified for each sample
(K) Three cancer/testis (CT) antigens overexpressed by at least 2-fold in tumors co
in brackets. Sample order is the same as in (J). Gray boxes indicate data are not
See also Figures S4 and S5 and Tables S5 and S6.
1042 Cell 177, 1035–1049, May 2, 2019tumor-NAT pairs. Eight proteins were increased in tumor in
more than 95% of the pairs, including DDX21 (100%),
S100A11 (100%), RSL1D1 (99%), S100P (97%), RPL36A
(97%), PLOD2 (96%), SERPINH1 (95%), and GPRC5A (95%).
Among the 30 proteins with immunohistochemistry (IHC) stain-
ing data in The Human Protein Atlas (HPA), around half showed
medium to strong tumor-specific staining in CRC samples (Fig-
ures 5D and S4).
We associated the 31 proteins with the human secretome,
membrane proteome, and enzymes because these sub-
proteomes are enriched with clinically approved biomarkers
and drug targets. Nineteen have been found in plasma, 18 are
secreted, nine are trans-membrane, and eight are enzymes (Fig-
ure 5E). Fifteen of these proteins have known clinical utilities as
diagnostic markers, outcome markers, or therapeutic targets
(Table S5), including CEACAM5, which is the most widely used
CRC marker in clinical practice (Duffy, 2001). Other proteins
may merit further investigation.
We also assessed the differences in phosphorylation site
abundance between 96 tumor and NAT pairs. Among the
7,295 phosphorylation sites quantified in at least 50% of the
paired samples, 2,119 (29%) were significantly increased and
3,053 (42%) were significantly decreased in tumors compared
to paired NATs (adj. p < 0.01, Wilcoxon signed-rank test).
Of these, 63 were increased and 793 were decreased
with a >2-fold abundance change (Figure 5F). We defined
the 63 phosphosites mapping to 50 proteins as cancer-
associated phosphosites (Table S5), of which all but one
had greater changes in phosphosite abundance than in corre-
sponding protein abundance (Figure 5G, red dots). Despite
the overall concordance between phosphosite abundance
changes and corresponding protein abundance changes
(Pearson’s r = 0.81, p < 2.2 3 1016), some cancer-associated
phosphosites mapped to proteins that were decreased in
tumor samples (Figure 5G, highlighted by black arrows). Only
four of the 50 proteins with a cancer-associated phosphosite
also met our criteria as cancer-associated proteins. Moreover,
only seven proteins in our combined protein set wereissues (NATs, light red and blue colors indicate adj. p < 0.01 (sig) whereas red
y.
ulated in tumors. Venn diagram depicts the overlap between muscle system
cer-associated proteins (mean in red).
e Human Protein Atlas (HPA).
d enzymes annotated by HPA, as well as known clinical utilities.
rs are the same as in (A).
nce differences (Pearson’s r = 0.81, p < 2.2 3 1016). The purple dashed line
fold increase. The black arrows highlight 5 of these phosphorylation sites with
hoproteome), cancer-associated proteins (proteome), and cancer genes in the
wn kinase activating site in tumor compared to NAT (phosphorylation) or by
ips (inferred). Gray boxes indicate data are not available. Black boxes indicate
ting that kinase.
, with MSI-H and MSS annotation shown at the top.
mpared to NATs in more than 5% of all samples, with the percentage indicated
available.
documented in the Cancer Gene Census, a comprehensive
catalog of genes containing mutations implicated in cancer
(Figure 5H). Proteomics and phosphoproteomics data thus
are complementary and both reveal additional colon cancer
genes that were missed in genomic studies.
Kinases are among the most attractive therapeutic targets for
cancer treatment. We predicted cancer-associated kinase activ-
ity based on (1) significantly increased phosphorylation of a
known kinase activating site in tumor compared to NAT, and
on (2) enrichment analysis of the known target sites for each
kinase. We identified four kinases by each method, with
one kinase, CDK7, identified by both (Figure 5I). Among these
kinases, CDK4 is targeted by Food and Drug Administration
(FDA)-approved drugs, and the other CDKs (CDK1, CDK2, and
CDK7), MELK, and PFKFB3 are targeted by drugs in clinical
trials (Table S5). The last kinase, PI4KB, may merit further inves-
tigation as a novel candidate therapeutic target.
Tumor Antigens
To facilitate the development of personalized vaccines for can-
cer immunotherapy, we further analyzed our data to identify
candidate tumor antigens, including neoantigens derived from
somatic mutations and non-mutated cancer/testis (CT) antigens.
To identity candidate neoantigens, we searched the label-free
and TMT global proteomics and TMT phosphoproteomics data
against customized protein databases incorporating all coding
variations identified from matched exome sequencing and
RNA-seq data and found 173 proteomics-supported somatic
mutations. All peptides of 9–11 amino acids in length that con-
tained one of these somatic mutations were evaluated for
human leukocyte antigen (HLA)-I binding affinity. The 88 mutant
peptides with high predicted binding affinity to HLA molecules
were considered as putative neoantigens (Table S6). In total,
one or more putative neoantigens were identified for 38% of
the tumors (Figure 5J).
The TMT global proteomics data identified a total of 16
CT-antigens, and three were increased by at least 2-fold in
tumors compared to paired NATs in more than 5% of all
tumor-NAT pairs, including IGF2BP3 (51%), SPAG1 (14%), and
ATAD2 (8%) (Figure 5K). According to data in HPA, IGF2BP3
protein expression in normal human tissues is restricted to
reproductive organs and fetal brain (Figure S5A). While normal
colon tissue stains negatively for IGF2BP3, colon cancer stains
positively (Figure S5B). Notably, peptides derived from IGF2BP3
significantly induce a tumor-specific cytotoxic T lymphocyte
response in vitro (Suda et al., 2007) and in vivo in human esoph-
ageal tumors in a phase I clinical trial (Kono et al., 2009).
In contrast to neoantigens that were enriched in MSI-H tumors
and were patient-specific, CT antigens were independent of MSI
status and were shared among many patients. Together, we
found proteomics-supported neoantigens or CT antigens for
78% of the tumors in this cohort, demonstrating the potential
of proteogenomics in identifying tumor antigens for cancer vac-
cine development.
A Unified View of Colon Cancer Molecular Subtypes
Applying the consensus molecular subtypes (CMS) classifier
(Guinney et al., 2015) to 106 tumors with RNA-seq data, we as-signed 85 (80%) of these tumors to the four transcriptomic sub-
types (CMS1–CMS4, Figure S6A). Applying the CRC proteomic
subtype classifier (Zhang et al., 2014) to 100 tumors with label-
free proteomics data, we assigned 88 (88%) of these tumors to
the five proteomic subtypes (ProS-A–ProS-E, Figure S6B), and
this protein expression pattern was largely preserved in the
TMT proteomics data (Figure S6C). These results provided inde-
pendent validation of the previously published molecular classi-
fication systems.
To test for underlying consistency among the mRNA, protein
and MSI-based classifications, we constructed a network in
which nodes represent the subtypes from individual classification
systems, and weighted edges represent statistically significant
association between two subtypes and the level of significance
(Figure 6A). All these associations were confirmed in the TCGA
CRC cohort. The connected subtypes in the association network
fell naturally into three groups, as indicated by the dashed circles
in Figure 6A. The grouping aligned well with previous transcrip-
tomic and proteomic studies that independently associated
CMS1 and ProS-B with MSI-H and hypermutation, CMS2 and
ProS-E with chromosome instability (CIN), and CMS4 and ProS-
C with epithelial-mesenchymal transition (EMT) (Guinney et al.,
2015; Zhang et al., 2014). Accordingly, we named the three unified
multi-omics subtypes (UMS) as ‘‘MSI,’’ ‘‘CIN,’’ and ‘‘Mesen-
chymal,’’ respectively. Using a network centrality-basedweighted
voting algorithm, we assigned 87 out of the 110 tumor samples to
the three UMS subtypes (Figure 6B). The UMS classification elim-
inated the CMS3 subtype and assigned CMS3 tumors to other
UMS subtypes. This was explained by the vague molecular
boundary of the CMS3 subtype (Figures S6D–S6F). In addition,
three MSI-H tumors with relatively fewer MS INDELs were as-
signed to the Mesenchymal subtype.
Next, we performed subtype-based supervised analysis on
omics data not used in defining the UMS classification. Tumors
in the CIN subtype showed higher chromosome instability
compared to those in the other two subtypes (p < 0.01, t test, Fig-
ures 6C and S6G), providing orthogonal confirmation of the UMS
classification. Similarly, many of the miRNA and phosphosite
markers identified in the supervised analysis (Table S7) have
known relationships with the subtype-specific features. Exam-
ples include decreased expression of miR-552, miR-592, and
miR-181d in the MSI subtype (Liu and Zhang, 2016), decreased
expression of the miR-200 family in the Mesenchymal subtype
(Korpal et al., 2008), and increased phosphorylation of STAT1
and STAT3 in the MSI and Mesenchymal subtypes, respectively
(Pensa et al., 2009). Notably, we found higher copy-number gain
of RB1 in the CIN subtype compared to the other subtypes (Fig-
ure S6H). Moreover, Rb-S811 and S807 were significantly
increased in the CIN subtype compared to the other subtypes
(1.61- and 1.51-fold, respectively), and the increase was much
stronger than that of total Rb (1.13-fold, Table S7). These results
complement our interpretation of the role of Rb phosphorylation
in colon cancer and further suggest that CDK2 inhibition may be
the most effective in the CIN subtype.
To understand the UMS classification in the context of tumor
microenvironment, we performed in silico deconvolution to
quantify stromal infiltration level, immune infiltration level, and
tumor-infiltrating lymphocyte (TIL) subpopulations based onCell 177, 1035–1049, May 2, 2019 1043
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Figure 6. A Unified, Multi-omics View of Colon Cancer Subtypes
(A) The network representing the association between subtypes defined by genomic (black), transcriptomic (white), and proteomic (gray) classification systems.
Edge width denotes the significance of the connections computed by the Fisher’s exact test. The dashed circles indicate the three unified multi-omics sub-
types (UMSs).
(B) UMS assignment for samples in the cohort. The genomic, transcriptomic, and proteomic subtypes are also shown for comparison.
(C) Copy-number alteration data grouped by the three UMSs.
(D) Stroma and immune infiltration profiles grouped by the three UMSs. The cytotoxic immune cell cluster is highlighted by blue in the dendrogram.
See also Figure S6 and Table S7.RNA-seq data. Total stromal infiltration was significantly higher
in the Mesenchymal subtype compared to the other two sub-
types (Figure 6D). Although both the MSI and the Mesenchymal
subtypes had higher immune infiltration than the CIN subtype,
the MSI subtype was specifically enriched with cytotoxic
immune cells, such as NK cells and activated CD8 T cells,
whereas the Mesenchymal subtype was enriched with suppres-
sor immune cells, such as myeloid-derived suppressor cells
(MDSCs), macrophages, and Treg cells (Figure 6F). The UMS
classification thus provided a unified view of three major sub-
types of colon cancers with distinct genomic, transcriptomic,
proteomic, and microenvironment profiles.
Increased Glycolysis in the MSI Subtype Is Associated
with Immune Suppression
Despite the enrichment of cytotoxic immune cells in themicroen-
vironment, MSI tumors develop and progress, which has been
explained by the selective upregulation of immune checkpoint
proteins in the tumor microenvironment (Llosa et al., 2015).
However, only a subset of MSI-H CRCs respond to immune
checkpoint inhibitors (Le et al., 2015), suggesting a role for other
immune evasion mechanisms.
Comparison of protein and mRNA profiles between the MSI
subtype and the other UMS subtypes revealed a broad increase
of the glycolytic enzymes in theMSI subtype (Figure 7A). We also
found an almost universal decrease in tricarboxylic acid (TCA)1044 Cell 177, 1035–1049, May 2, 2019cycle enzymes at the protein level, but not at the mRNA level.
Thus, our data revealed protein-level adaptations driving a
strong Warburg effect in the MSI subtype.
Lactate, a key product of Warburg effect, is a potent inhibitor
of CD8 T cells (Brand et al., 2016). Indeed, almost all glycolytic
enzymes were negatively correlated with CD8 infiltration in MSI
tumors (Figure 7B). Using the median protein abundance of all
glycolytic enzymes as a measure of glycolytic activity, we found
a statistically significant negative correlation between glycolytic
activity and CD8 infiltration (Spearman’s r = 0.61, p = 0.02,
Figure 7C). Interestingly, this relationship was not observed in
other colon cancer subtypes or when all colon tumors were
analyzed together (Figure S7). The interplay between metabolic
reprogramming and immune function may apply specifically to
immune evasion and checkpoint inhibition resistance in the MSI
subtype.
To validate these findings, we performed targeted analysis of
selected proteins in representative tumor samples using
selected reaction monitoring (SRM). The SRM measurements
were highly correlated with TMT measurements for the CD8
T cell marker CD8A (Figure 7D) and the glucose transporter
SLC2A3 (Figure 7E). Pyruvate kinase PKM, the rate-limiting
glycolytic enzyme that catalyzes the last step of glycolysis,
has two isoforms. The targeted SRM analysis also was able to
measure isoform-specific peptides that were not detected in
the TMT analysis, thereby clarifying that PKM2 was the major
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Figure 7. Increased Glycolysis in the MSI Subtype and Its Association with CD8 T Cell Infiltration
(A) MSI subtype-specific alteration of key enzymes involved in the glycolysis and TCA cycle. The MSI subtype-specific RNA and protein changes are shown
side-by-side. p values were calculated based on the Wilcoxon rank sum test.
(B) The heatmap showing the protein expression levels of glycolytic enzymes within the MSI subtype. Samples are ordered by increased infiltration of activated
CD8 T cells.
(C) The negative correlation between glycolytic activity (inferred by the protein expression of enzymes involved in the pathway) and the activated CD8 T cell level
for the MSI subtype.
(D–G) Strong positive correlations were observed between SRM and TMT measurements for CD8A(D), SLC2A3 (E), and PKM2 (F), but not for PKM1 (G).
(H) SRM data showed higher CD8A abundance in MSI/CD8-H tumors (n = 5) than MSI/CD8-L tumors (n = 5).
(I–K) SRMdata showed higher protein abundance of SLC2A3 (I) and PKM2 (J) inMSI tumors (n = 10) compared to CIN (n = 5) andMesenchymal (n = 5) tumors, and
in MSI/CD8-L tumors (n = 5) compared to MSI/CD8-H tumors (n = 5). This pattern was not observed for PKM1 (K).
(L) Schematic diagram summarizing the interplay between glycolysis and CD8 T cell activation in MSI tumors, highlighting glycolysis as a potential target to
overcome the resistance of MSI-H tumors to immune checkpoint blockade.
The p value in (C) was calculated by Spearman’s correlation test; the p values in (D)–(G) were calculated by Pearson’s correlation test; the p values in (H)–(K) were
calculated by t test. See also Figure S7.isoform measured in the TMT analysis (Figures 7F and 7G). It is
known that PKM2, rather than PKM1, drives aerobic glycolysis
and lactate production in human cancer (Christofk et al.,
2008). MSI tumors with relatively higher amounts of estimated
activated CD8 cells (MSI/CD8-H) had 2.23-fold higher CD8A
abundance than those with lower amounts (MSI/CD8-L, Fig-
ure 7H), although the difference was not statistically significant,
likely due to the expression of CD8A in both activated and inac-
tivated CD8 cells. In the subtype-based comparisons (Figures
7I–7K), the abundance of SLC2A3 and PKM2 was 1.85- and
1.4-fold higher (p = 0.007 and 0.003, respectively, t test) in the
MSI subtype compared to the other two subtypes. Within theMSI subtype, SLC2A3 and PKM2were 1.19- and 1.7-fold higher
in the MSI/CD8-L tumors compared to the MSI/CD8-H tumors.
These data were consistent with the global proteomics data.
Taken together, our data support the model depicted in Fig-
ure 7L and suggest that combined therapy of checkpoint and
glycolysis inhibition may provide a potent strategy to treat MSI
tumors resistant to checkpoint blockade.
DISCUSSION
We performed an unprecedented molecular characterization of
human colon cancer and paired NATs with comprehensiveCell 177, 1035–1049, May 2, 2019 1045
integration of data from multiple proteogenomic platforms.
Our study confirmed the value of proteogenomic integration
in uncovering novel cancer biology and further demon-
strated the utility of proteogenomics in therapeutic hypothesis
generation.
We combined the customized proteomics database
approach with HLA binding prediction and identified personal-
ized neoantigens for 38% of the patients. mRNA expression
has been used to prioritize somatic mutations for personalized
neoantigen vaccine development, but proteomics-based
filtering prioritizes more effectively because neoepitopes them-
selves are peptides.
Colon cancer-associated proteins and phosphosites identi-
fied from our tumor versus NAT comparisons had very little
overlap with known cancer genes in the Cancer Gene Census
(Figure 5H), providing a novel information layer to our under-
standing of colon cancer. Notably, several CT antigens were
recurrently overexpressed in tumors. In addition to serving as
putative tumor-specific biomarkers, the inherent immunoge-
nicity of CT antigens, as demonstrated by IGF2BP3 in esopha-
geal cancer (Kono et al., 2009; Suda et al., 2007), makes them
potentially ideal targets for immunotherapy, especially for
MSS colon tumors that are poor candidates for checkpoint inhi-
bition or neoantigen vaccine treatment because of their low
neoantigen load.
Our multi-omics-based subtype analysis provided a unified
view of colon cancer molecular heterogeneity based on three
UMS subtypes (i.e., MSI, CIN, and Mesenchymal). Proteomics
data associated decreased CD8 infiltration with increased
glycolysis in MSI tumors, which supports the emerging view
that increased tumor glycolysis suppresses anti-tumor immunity
by impairing T cell function and trafficking to the tumor microen-
vironment (Tang and Fu, 2018). Therefore, glycolysis inhibition
may be considered to overcome the resistance of MSI tumors
to immune checkpoint blockade.
In addition to reinforcing or complementing genomics data,
proteogenomic integration also may correct inaccurate geno-
mics data-based inferences and lead to unexpected discov-
eries and therapeutic opportunities. One example is the
proteomic identification of SOX9 as an oncogene, whereas it
was predicted to be a tumor suppressor based on somatic
mutation data. Another example is the phosphoproteomics
data-enabled discovery of Rb phosphorylation as an onco-
genic driver of colon cancer, suggesting a unique opportunity
to target Rb phosphorylation in colon cancer through CDK2
inhibition.
In summary, our integrative proteogenomic characterization
revealed new therapeutic opportunities for targeting signaling
proteins, metabolic enzymes, and tumor antigens in colon
cancer treatment. Although validation of these therapeutic
hypotheses is beyond the scope of our current study, these
new hypotheses may eventually enable substantial advances
in molecularly guided precision therapy of colon cancer.
Further interrogation of this deeply characterized colon cancer
cohort by other investigators will likely yield additional in-
sights. The primary and processed datasets are available in
publicly accessible data repositories and portals (Figure 1A;
STAR Methods), and we anticipate broad usage of these data-1046 Cell 177, 1035–1049, May 2, 2019sets for new biological discoveries and therapeutic hypothesis
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Specimens and Clinical Data
Tumor, adjacent normal, and blood samples were collected by several tissue source sites in strict accordance to the CPTAC-2 colon
procurement protocol (https://brd.nci.nih.gov/brd/sop/download-pdf/321) with an informed consent from the patients. The
WashingtonUniversity inSt. Louis Institutional ReviewBoard (IRB) reviewed the individual informedconsent documents at each tissue
source site and determined that the materials sent to the CPTAC biospecimen core resource met the requirements for Exemption 4.
The cohort had an inclusion criterion of newly diagnosed, untreated patients undergoing primary surgery for colon adenocarcinoma.
Because untreated rectal tumors are difficult to obtain, we only included colon cancers, which represent approximately 70% of all
CRCs. Patientswith prior history of othermalignancieswithin 12months, any systemic chemotherapy, endocrine or biological therapy
as well as prior radiation therapy to the abdomen or pelvis for any cancer type were excluded from the study. Required clinical infor-
mation regarding patient history and status of surgery along with relevant diagnostic information were collected using case reports
forms.Oneyear followup informationwith updatedhistory after completionof the initial treatment regimenwerealsocollected through
followup forms.Deidentifiedpathology reports and representative diagnostic slide imageswereutilized to reviewandqualify cases for
this study. The peripheral venous blood from the same patient were collected prior to administration of anesthesia. Segments from
qualified tumor specimenswere greater than 300mg inmasswith at least 60% tumor cell nuclei and less than 20%necrosis. To ensure
tissue suitability for phosphoprotein analysis, the tissue and the adjacent normal specimens were collected in less than
30 minutes total ischemic time and embedded in optimal cutting temperature (OCT) compound for processing at a common
CPTAC-2 specimen core resource center. Pathologically qualified cases underwent further molecular qualification for extraction
and co-isolation of nucleic acids. Tissue segments that were pathology and molecular qualified were shipped to the proteomic
characterization centers. DNAandRNA from the same tumor segment andDNA fromgermline bloodwere further aliquoted andquan-
tified per protocol. DNA quality was confirmed using gel electrophoresis and Nano drop methods. RNA quality was confirmed using
Nano drop andAgilent bioanalyzer. Sufficient yield, a good gel score and passing value of 7 or greater RIN qualified theDNAandRNA,
respectively, for sequencing. The analytes were then shipped to the sequencing center. The corresponding clinical data were
formatted and distributed through the CPTAC data coordinating center (https://cptac-data-portal.georgetown.edu/cptac/s/S037).
Table S1 summarizes the clinical and pathological characteristics of the tumors and the specific numbers of samples analyzed by
each omics platform. Among the 110 patients in the cohort, there were 65 females (60%) and 45 males (40%), with an average age
of 65 (range 40 to 93 years). We did not perform analyses on the two sexes separately because the sample size is too small after
sex stratification. Moreover, we were interested in results common to both sexes, and the sex distribution is reasonably balanced.
METHODS DETAILS
PCR-based MSI Analysis
The MSI Analysis System (version 1.2, Promega), a fluorescent PCR-based assay, was used to detect microsatellite instability (MSI)
in the colon tumors. The analysis compares allelic profiles of microsatellite markers generated by amplification of DNA frommatching
tumor and normal samples, and alleles that are present in the tumor sample but not in corresponding normal samples indicate MSI.
The system uses sevenmarkers including fivemononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, andMONO-27) and
two pentanucleotide repeat markers (Penta C and Penta D). The output data were analyzed with GeneMapper software (Applied
Biosystems) to determine MSI status of the colon tumor samples.
Genotyping Array Analysis
Genomic DNA samples were prepared according to Illumina’s Infinium LCG Quad Assay manual protocol. Processed samples were
loaded on the HumanOmni5-Quad BeadChips and run on the HiScan platform. SNP and CNP genotyping were performed with the
Genome Studio Genotyping Module (Version 2.0, Illumina).
Whole Exome Sequencing
Genomic DNA samples were used to prepare indexed libraries using the Nextera Rapid Capture Exome kit from Illumina. Library
preparation was performed using a semi-automated 96-well plate method, with washing and clean-up/concentration steps per-
formed on the Beckman Coulter Biomek NXP platform and with ZR-96 DNA Clean & Concentrator-5 plates, respectively. Libraries
were quantified using the Agilent 2100 Bioanalyzer. Pooled libraries were run on HiSeq4000 (2x150 paired end runs) to achieve a
minimum of 150x on target coverage per each sample library. The raw Illumina sequence data were demultiplexed and converted
to fastq files, adaptor and low-quality sequences were trimmed. Whole exome sequencing (WXS) data were used for somatic
mutation detection, microsatellite instability prediction, and somatic copy number alteration (SCNA) analysis as described below.
Somatic Mutation Detection
We followed the Genome Analysis Toolkit (GATK, version 3.8.0) best practice guideline for somatic short variant discovery (https://
software.broadinstitute.org/gatk/best-practices/workflow?id=11146). Briefly, we aligned paired-endWXS reads to the human refer-
ence genome (hg19) with BWA-mem (version 0.7.15-r1140). The bam files were further processed by adding read groups, markinge3 Cell 177, 1035–1049.e1–e11, May 2, 2019
duplicates, and re-ordering with Picard tools (version 2.9.0). Consequently, base quality score recalibration and INDEL realignment
were performed using GATKmodules IndelRealigner and BaseRecalibrator. The cross-individual contamination was then estimated
by the GATK module ContEst. Single nucleotide variants (SNVs) and INDELs (insertions/deletions) were called from tumor and
matched-normal pairs using MuTect2 from GATK. We filtered out variants from short tandem repeat regions, which were down-
loaded from the UCSC table browser. The sequence variants were then annotated using customProDB and Oncotator. Significance
of candidate mutations was evaluated in non-hypermutated and hypermutated tumors separately using MutSigCV (version 1) in
GenePattern, and geneswith a false discovery rate (q value) below 0.05were considered significantlymutated above the background
mutation rate.
Germline Short Variant Discovery from WXS
We followed the GATK best practice guideline for germline short variant discovery from WXS data (https://software.broadinstitute.
org/gatk/best-practices/workflow?id=11145). We started from the processed bam files generated in the previous section. Haploty-
peCaller was used to generate an intermediate file, GVCF, for each sample. Next, we consolidated all GVCFs from 106 samples into
to one GVCF file using the GATK module CombineGVCF. The merged GVCF file was passed to GenotypeGVCFs, a joint genotyping
tool for SNP and INDEL calling. We further filtered the variants by variant quality score recalibration, in which machine learning was
used to identify annotation profiles of variants likely to be real.
Microsatellite Instability Prediction
MSMuTect (version 1.0) (Maruvka et al., 2017) was applied to the processed bam files for somatic microsatellite INDEL (MS INDEL)
calling. MSMuTect uses the Kolmogorov–Smirnov (KS) test to identify microsatellite sites with different alleles between tumor and
normal samples. Using tumors with PCR test results, we found that the Fisher’s exact test provided higher sensitivity and specificity
compared to the KS test. Therefore, we applied Fisher’s exact test to the histograms generated by MSMuTect and then used the
Fisher’s exact test p-value as the filtering criterion, with a p-value cutoff of 0.001. We named this modified methodMSMuTect-fisher.
Significant MS INDELs with multiple alleles in normal and only one allele in tumor were removed from further analysis. Using 40 MS
INDELs as a cutoff, we separated the samples into anMSI-high (MSI-H) group and amicrosatellite stable (MSS) group. MSMutSigCV
(Maruvka et al., 2017) was used to detect significantly mutated genes based on identified MS INDELs (p < 0.05).
Annotation of Protein Altering Somatic Mutations
All somatic mutations identified by MuTect2 and MSMuTect, including SNVs, INDELs, and MS INDELs, were annotated using
ANNOVAR (Wang et al., 2010). The variants obtained by ANNOVAR were filtered for protein altering events including non-
synonymous SNVs, frameshift INDELs, non-frameshift INDELs, and stop gains. Table S3 includes all isoforms altered by the somatic
mutation events. For the analysis of proteomic consequence, the longest isoform was selected for each somatic mutation event.
Somatic Copy Number Alteration Analysis
Somatic copy number alteration (SCNA) analysis usedWXS-derived BAMfiles that were processed in the somaticmutation detection
pipeline. These BAMfiles were further processed by the RPackageCopywriteR (version 1.18.0) (Kuilman et al., 2015), which uses off-
target WXS reads to infer copy number values. 105 tumor and matched-normal pairs had sufficient (> 5 million) off-target reads for
SCNA detection as recommended by the software (Kuilman et al., 2015). The circular binary segmentation (CBS) algorithm (Olshen
et al., 2004) which is also implemented in the CopywriteR package was used for the copy number segmentation, with the default
parameters. From the segmentation result, we used a weighted-sum approach to summarize the chromosome instability for each
sample. Specifically, the absolute log2 ratios of all segments (indicating the copy number aberration of these segments) within a
chromosome were weighted by the segment length and summed up to derive the instability score for the chromosome. The
genome-wide chromosome instability index was derived by summing up the instability score of all 22 autosomes.
Next, we used GISTIC2 (version 2.0.23) (Mermel et al., 2011) to retrieve gene-level copy number values and call significant copy
number alterations in the cohort. We set up a threshold of 0.4 (-ta and -td parameters of GISTIC2) in picking the amplified or deleted
regions based on the distribution of germline copy number variants. Moreover, genome regions containing significant numbers of
germline copy number variants were excluded from the GISTIC2 population level statistics (the -cnv parameter of GISTIC2). GISTIC2
generated arm level and focal level SCNAs for the cohort with G-Score and FDR Q value indicating the significance and strength of
the identified SCNAs.
In order to prioritize SCNA drivers, we selected all the genes located in the focal region with GISTIC2 Q value less than 0.25. Also,
we included genes located in the ‘‘wide peaks’’ identified by GISTIC2. For these genes, spearman correlation was calculated
between copy number values and their RNA or protein levels across the cohort. We used FDR less than 0.05 and absolute correlation
coefficient larger than 0.3 as the cutoff to select candidate genes. As an additional filtering criterion, we further required candidate
amplification and deletion drivers to show significant upregulation and downregulation, respectively, in tumor versus matched
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mRNA Sequencing
Indexed cDNA sequencing libraries were prepared from the RNA samples using the TruSeq Stranded RNA Sample Preparation Kit
and bar-coded with individual tags. Library preparation was performed similarly to the WXS. Quality control was performed at every
step, and the libraries were quantified using the Agilent 2100 Bioanalyzer. Indexed libraries were prepared as equimolar pools and run
on HiSeq4000 (2x150 paired end runs) to generate a minimum of 30 million paired-end reads per sample library. The raw Illumina
sequence data were demultiplexed and converted to. fastq files, and adaptor and low-quality sequences were trimmed.
RNA Quantification
mRNA sequencing reads were mapped to the human genome hg19 by STAR (version 2.5.3a) using the 1-pass model. Hg19
sequence and RefSeq annotation were downloaded from the UCSC table browser (03/29/2017). RSEM (version 1.2.31) was used
to quantify genes and transcripts expression levels. Gene read counts were calculated using HTseq (version 0.7.2). The RSEM out-
puts the mRNA RSEM and FPKM (Fragments Per Kilobase of transcript per Million mapped reads) results in table format. The mRNA
RSEM data were filtered for genes with median FPKM > 1 for use in downstream analyses.
Short Variant Discovery from RNA-Seq
We followed theGATKBest Practice Variant Detection protocol on RNASeq (https://gatkforums.broadinstitute.org/dsde/discussion/
3892/the-gatk-best-practices-for-variant-calling-on-rnaseq-in-full-detail). We used the STAR 2-pass method to align RNA-Seq
reads to the human reference genome (hg19). Specifically, splice junctions detected in the 1-pass alignment run were used to guide
the 2-pass alignment. After alignment, the SAM file was processed through the usual Picard processing steps including adding read
group, sorting, marking duplicates, and indexing. Next, we applied the GATK pipeline including the modules ‘SplitNCigarReads’,
‘HaplotypeCaller’ and ‘VariantFiltration’. The minimum phred-scaled confidence threshold for calling variants was set to 20. The
‘VariantFiltration’ module excluded SNVs with: a quality by depth score (QD) < 2.0, a Fisher strand score (FS) > 30.0, or clusters
of at least 3 SNPs that were within a window of 35 bases between them. These filters ensured: (1) high confidence variant calls based
on unfiltered depth of non-reference samples (QD); (2) low strand bias for detection of variants (FS)—as strand bias is indicative of
false positive calls; and (3) filtering of many false variant calls introduced by RNA-Seq read mapping errors.
miRNA Sequencing
Indexed small RNA sequencing libraries were prepared from the RNA samples using the TruSeq Small Total RNA Sample Prep Kit,
and bar-coded with individual tags. Library preparation was performed similarly to the WXS sequencing. Quality control was
performed at every step, and the libraries were quantified using the Agilent 2100 Bioanalyzer. Indexed libraries were prepared as
equimolar pools and loaded on the NextSeq500 (1x75 single read) run to generate at least 5,000,000 single reads per sample library.
The raw Illumina sequence data were demultiplexed and converted to fastq files.
miRNA-Seq Data Analysis
For fastq files frommiRNA sequencing, adapters were trimmed usingCutadpt (version 1.13) with amaximumallowed error rate of 0.1.
Trimmed reads shorter than 17 or longer than 26 nucleotides in length were excluded from further analysis. Reads were thenmapped
to the human genome hg19 using Bowtie (version 1.1.1). Mapped reads were then annotated using ncPRO-seq (version 1.6.1) based
on the ncPRO-seq hg19 annotation. Mature miRNA annotation was extended 2 bp in both upstream and downstream regions to
accommodate inaccurate processing of precursor miRNAs. ncPRO-seq outputs miRNA count and RPM (reads per million mappable
reads) results in table format.
Label-free Proteomics Analysis
Label-free shotgun proteomic analyses of the colon tumor samples were done according to the methods described previously
(Zhang et al., 2014), with two changes. First, 6 concatenated basic reverse phase LC fractions were prepared from tryptic digests
using the same instrumentation described previously. Second, LC-MS/MS analyses were done with a ThermoFisher QExactive
MS instrument. LC-MS/MS shotgun proteomics of the concatenated fraction samples were carried out on a Q Exactive mass spec-
trometer (ThermoFisher Scientific) equipped with an Easy nLC-1000 (ThermoFisher Scientific) and a Nanoflex source (ThermoFisher
Scientific). A 2 mL injection volume of peptides were separated on a PicoFrit (New Objective, Woburn, MA) column (75 mm ID x
110 mm, 10 mm ID tip) packed with ReproSil-Pur C18-AQ resin (3 mm particle size and 120 A˚ pore size). Peptides were eluted at a
flow rate of 300 nL/min, and the mobile phase solvents consisted of water containing 0.1% formic acid (solvent A) and acetonitrile
containing 0.1% formic acid (solvent B).
A 100-minute gradient was performed, consisting of the following: 05 min, increase to 5% B; 5-90 min, 535% B; 90-93 min,
90%B; 93-100min, 90%B and held at 90%B for 7min before returning to the initial conditions of 2%B.Mass spectra were acquired
over the scan range of m/z 300-1800 at a resolution of 70,000 (AGC target 3 x106 and 64 ms max injection time). Data-dependent
scans of the top 20 most abundant ions were selected for fragmentation with HCD using an isolation width of 2m/z, 27% normalized
collision energy and a resolution of 17,500 (AGC target 2 x105 and 100 ms max injection time). Dynamic exclusion was set to 60 s.e5 Cell 177, 1035–1049.e1–e11, May 2, 2019
Label-free Proteomics Data Analysis
The rawMSdata were converted toMGF andmzML files using ProteoWizard (version 3.0.10462). TheMS/MSdata were searched by
three search engines (MyriMatch version 2.2.10165, X!Tandem version Alanine 2017.02.01, and MS-GF+ version 2017.01.13)
through IPeak (Wen et al., 2014, 2015) against the RefSeq protein database (03/29/2017, 45929 sequences + 245 contaminant se-
quences) with decoy sequences. The following parameters were set for database searching: Carbamidomethyl (C) was specified as a
fixed modification. Oxidation (M) and Deamidated (NQ) were specified as variable modifications. The precursor mass tolerance for
protein identification on MS was 10 ppm, and the product ion tolerance for MS/MS was 0.05 Da. Full cleavage by trypsin was used,
with up to two missed cleavages permitted. The results from the three search engines were then integrated by IPeak, which is a tool
that combines multiple search engine results. To optimize the number of proteins identified we applied a very stringent filter at 0.1%
PSMFDR. Then the protein inference was performed and 1%FDRwas controlled using the ‘‘picked’’ protein FDR approach (Savitski
et al., 2015). To rescue high quality PSMs that were excluded by the stringent PSMFDR threshold, we relaxed the PSMFDR threshold
to 1% for the confidently identified proteins.
Spectral count data were filtered by removing proteins with zero counts in all samples and quantile-normalized using the R pack-
age preprocessCore (version 1.42.0, https://github.com/bmbolstad/preprocessCore). We further filtered low abundant proteins with
average raw count < 1.4 as we did previously (Zhang et al., 2014). The normalized and filtered counts were then log2 transformed for
downstream analysis.
Protein Extraction and Tryptic Digestion for TMT Analysis
For TMT analysis, the tumor and normal colon tissue samples were obtained as OCT-embedded tissue curls through the CPTAC
Biospecimen Core Resource. Approximately 100 mg of each of the samples were first subjected to OCT removal procedure by
sequential rinsing in 70% ethanol, nanopure water, and 100% ethanol. The tissue samples were then homogenized separately in
600 mL of lysis buffer (8 M urea, 100 mM NH4HCO3, pH 7.8, 75 mM NaCl, 1 mM EDTA, 10 mM NaF, Sigma phosphatase inhibitor
cocktail 2, Sigma phosphatase inhibitor cocktail 3, and 20 mM PUGNAc). Lysates were precleared by centrifugation at 16,500 g
for 5 min at 4C and protein concentrations were determined by BCA assay (Pierce). Proteins were reduced with 5 mM dithiothreitol
for 1 h at 37C, and subsequently alkylated with 10 mM iodoacetamide for 45 min at 25C in the dark. Samples were diluted 1:2 with
100 mM NH4HCO3, 1 mM CaCl2 and digested with sequencing grade modified trypsin (Promega) at 1:50 enzyme-to-substrate ratio.
After 3 h of digestion at 37C, samples were diluted 1:4 with the same buffers and another aliquot of the same amount of trypsin was
added to the samples and further incubated at 25C overnight (16 h). The digested samples were then acidified with 100% formic
acid to 1% formic acid in the final sample solution. Tryptic peptides were desalted on reversed phase C18 SPE columns (Waters tC18
SepPak, 200mg) and dried using Speed-Vac.
TMT-10 Labeling of Peptides
Desalted peptides from each sample were labeled with 10-plex Tandem Mass Tag (TMT) reagents according to the manufacturer’s
instructions (ThermoScientific). Peptides (300 mg) from each of the samples were dissolved in 300 mL of 50 mM HEPES, pH 8.5, and
mixed with 3 units of TMT reagent that was dissolved freshly in 123 mL of anhydrous acetonitrile. Channel 131 was used for labeling
the internal reference sample (pooled from all tumor and normal samples with equal contribution) throughout the sample analysis.
After 1 h incubation at RT, 24 mL of 5% hydroxylamine was added and incubated for 15 min at RT to quench the reaction. Peptides
labeled by different TMT reagents were thenmixed, dried using Speed-Vac, reconstituted with 3% acetonitrile, 0.1% formic acid and
were desalted on C18 SPE columns (Waters tC18 SepPak, 200mg).
Peptide Fractionation by Basic Reversed-phase Liquid Chromatography
Approximately 2.5 mg of 10-plex TMT labeled sample was separated on a Waters reversed phase XBridge C18 column (250 mm 3
4.6 mm column containing 5-mm particles, and a 4.6 mm 3 20 mm guard column) using an Agilent 1200 HPLC System. After the
sample loading, the C18 column was washed for 35 min with solvent A (5 mM ammonium formate, pH 10.0), before applying a
100-min LC gradient with solvent B (5 mM ammonium formate, pH 10, 90% acetonitrile). The LC gradient started with a linear in-
crease of solvent A to 10% B in 6 min, then linearly increased to 30% B in 86 min, 10 min to 43% B, 5 min to 55% B and another
8 min back to 100% B. The flow rate was 0.5 mL/min. A total of 96 fractions were collected into a 96 well plate throughout the LC
gradient. These fractions were concatenated into 12 fractions by combining 8 fractions that are 12 fractions apart (i.e., combining
fractions #1, #13, #25, #37, #49, #61, #73, and #85; #2, #14, #26, #38, #50, #62, #74, and #86; and so on). For proteome analysis,
5% of each concatenated fraction was dried down and re-suspended in 2% acetonitrile, 0.1% formic acid to a peptide concentration
of 0.1 mg/mL for LC-MS/MS analysis. The rest of the concatenated fractions (95%) were further concatenated into 6 fractions by
combining two concatenated fractions (i.e., combining concatenated fractions #1 and #7; #2 and #8; and so on), dried down, and
subjected to immobilized metal affinity chromatography (IMAC) for phosphopeptide enrichment.
Phosphopeptide Enrichment Using IMAC
Fe3+-NTA-agarose beads were freshly prepared using the Ni-NTA Superflow agarose beads (QIAGEN) for phosphopeptide enrich-
ment. For each of the 6 fractions, peptides were reconstituted to 0.5 mg/mL in IMAC binding/wash buffer (80% acetonitrile, 0.1% for-
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were washed 2 times each with 100 mL of wash buffer on the stage tip packed with 2 discs of Empore C18material. Phosphopeptides
were eluted from the beads on C18 using 60 mL of Elution Buffer (500 mM K2HPO4, pH 7.0). 50% acetonitrile, 0.1% formic acid was
used for elution of phosphopeptides from the C18 stage tips. Samples were dried using Speed-Vac, and later reconstituted with
10 mL of 3% acetonitrile, 0.1% formic acid for LC-MS/MS analysis.
LC-MS/MS for TMT Global Proteome Analysis
The global proteome fractions were separated using a nanoAquity UPLC system (Waters Corporation) by reversed-phase HPLC. The
analytical columnwasmanufactured in-house using ReproSil-Pur 120C18-AQ 1.9 mmstationary phase (Dr.MaischGmbH) and slurry
packed into a 30-cm length of 360 mm o.d. x 75 mm i.d. fused silica containing a 3-mm sol-gel frit. The trapping column was
manufactured in-house using Jupiter 300 C18 5-mm stationary phase (Phenomenex) and slurry packed into a 4-cm length of
360 mm o.d. x 150 mm i.d. fused silica with the final column being sol-gel fritted on both ends. The analytical column was heated
to 50C using an AgileSLEEVE column heater (Analytical Sales and Services, Inc.). The analytical column was equilibrated to 95%
Mobile Phase A (MP A, 0.1% formic acid in water) and 5% Mobile Phase B (MP B, 0.1% formic acid in acetonitrile) and maintained
at a constant column flow of 200 nL/min. The sample injected (5-mL) was trapped using 100%MPA for 10min at flow rate of 3 mL/min
before being placed in-line with the analytical column and subjected to the gradient profile (min: %MP B): 0:5, 1:8, 44:15, 85:30,
94:55, 102:70, 105:95, 108:95, 115:5, 150:5.
MS analysis was performed using a Q-Exactive Plus mass spectrometer (Thermo Scientific, San Jose, CA). Electrospray voltage
(2.2 kV) was applied at a carbon composite union (Valco Instruments Co. Inc.) between the analytical column and electrospray emitter
(chemically etched 360-mmo.d. x 20-mm i.d.). The ion transfer tubewas set at 250C. Following a 15-min delay from the end of sample
trapping, Orbitrap precursor spectra (AGC 1x106) were collected from 300-1800m/z for 120minutes at a resolution of 70K along with
the top 12 data dependent Orbitrap HCDMS/MS spectra at a resolution of 35K (AGC 1x105) and max ion time of 100 msec. Masses
selected for MS/MS were isolated at a width of 0.7 m/z and fragmented using a normalized collision energy of 32%. Peptide match
was set to ‘Preferred’, exclude isotopes was set to ‘on’, and charge state screening was enabled to reject unassigned 1+, 7+, 8+, and
> 8+ ions with a dynamic exclusion time of 20 s to discriminate against previously analyzed ions.
LC-MS/MS for TMT Phosphoproteome Analysis
The phosphoproteome fractions were separated using a nanoAquity UPLC system (Waters Corporation) by reversed-phase HPLC.
The analytical column was manufactured in-house using ReproSil-Pur 120 C18-AQ 1.9 mm stationary phase (Dr. Maisch GmbH) and
slurry packed into a 35-cm length of 360 mm o.d. x 50 mm i.d. fused silica picofrit capillary tubing (New Objective, Inc.). The trapping
column was manufactured in-house using Jupiter 300 C18 5-mm stationary phase (Phenomenex) and slurry packed into a 4-cm
length of 360 mm o.d. x 150 mm i.d. fused silica with the final column being sol-gel fritted on both ends. The analytical column was
heated to 50C using an AgileSLEEVE column heater. The analytical column was equilibrated to 98%MP A and 2%MP B and main-
tained at a constant column flow of 120 nL/min. The sample injected (5 mL) was trapped using 100%MP A for 5 min at a flow rate of
3 mL/min before being placed in-line with the analytical column and subjected to the gradient profile (min:%MP B): 0:2, 8:4, 50:15,
85:35, 94:60, 95:95, 105:95, 115:2, 170:2.
MS analysis was performed using an Orbitrap Fusion Lumos mass spectrometer (Thermo Scientific). Electrospray voltage (1.8 kV)
was applied at a Valco carbon composite union coupling a 360 mm o.d. x 20 mm i.d. fused silica extension from the LC gradient
pump to the analytical column and the ion transfer tube was set at 250C. Following a 40-min delay from the end of sample
trapping, Orbitrap precursor spectra (AGC 4x105) were collected from 350-1800 m/z for 120 min at a resolution of 60K along with
data dependent Orbitrap HCD MS/MS spectra (centroided) at a resolution of 50K (AGC 1x105) and max ion time of 105 msec for
a total duty cycle of 2 s. Masses selected forMS/MSwere isolated (quadrupole) at a width of 0.7m/z and fragmented using a collision
energy of 30%. Peptide mode was selected for monoisotopic precursor scan and charge state screening was enabled to reject
unassigned 1+, 7+, 8+, and > 8+ ions with a dynamic exclusion time of 45 s to discriminate against previously analyzed ions between
± 10 ppm.
Quantification of TMT Global Proteomics Data
LC-MS/MS analysis of the TMT10-labeled, bRPLC fractionated samples generated a total of 264 global proteomics data files. The
Thermo RAW files were processed with DTARefinery (Petyuk et al., 2010) (v1.2) to characterize and correct for any instrument cali-
bration errors, and then with MS-GF+ (Kim et al., 2008; Kim and Pevzner, 2014) (v9881) to match against the RefSeq human protein
database (03/29/2017, 45929 sequences), combined with 261 contaminants (e.g., trypsin, keratin). The partially tryptic search used a
± 10 ppmparent ion tolerance, allowed for isotopic error in precursor ion selection, and searched a decoy database composed of the
forward and reversed protein sequences. MS-GF+ considered static carbamidomethylation (+57.0215 Da) on Cys residues and TMT
modification (+229.1629 Da) on the peptide N terminus and Lys residues, and dynamic oxidation (+15.9949 Da) on Met residues for
searching the global proteome data.
Peptide identification stringency was set at a maximum false discovery rate (FDR) of 1% at peptide level using PepQValue < 0.005
and parent ion mass deviation < 7 ppm criteria. A minimum of 6 unique peptides per 1000 amino acids of protein length was required
for achieving 1%at the protein level within the full dataset. Inference of parsimonious protein set resulted in the identification of a total
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The intensities of all ten TMT reporter ions were extracted using MASIC software (Monroe et al., 2008). Next, PSMs passing the
confidence thresholds described above were linked to the extracted reporter ion intensities by scan number. The reporter ion inten-
sities from different scans and different bRPLC fractions corresponding to the same gene were grouped. Relative protein abundance
was calculated as the ratio of sample abundance to reference abundance using the summed reporter ion intensities from peptides
that could be uniquely mapped to a gene. The pooled reference sample was labeled with TMT 131 reagent, allowing comparison of
relative protein abundances across different TMT-10 plexes. The relative abundances were log2 transformed and zero-centered for
each gene to obtain final, relative abundance values.
Small differences in laboratory conditions and sample handling can result in systematic, sample-specific bias in the quantification
of protein levels. In order to mitigate these effects, we computed the median, log2 relative protein abundance for each sample and
re-centered to achieve a common median of 0.
Quantification of Phosphopeptides
Phosphopeptide identification for the 132 phosphoproteomics data files were performed as described above (e.g., peptide level
FDR < 1%), with an additional dynamic phosphorylation (+79.9663 Da) on Ser, Thr or Tyr residues. The phosphoproteome data
were further processed by the Ascore algorithm (Beausoleil et al., 2006) for phosphorylation site localization, and the top-scoring
sequences were reported. For phosphoproteomics data, the TMT-10 quantitative data were not summarized by protein, but left
at phosphopeptide level. All the peptides (phosphopeptides and global peptides) were labeled with TMT-10 reagent simultaneously.
Separation into phospho- and non-phosphopeptides using IMAC was performed after the labeling. Thus, all the biases upstream of
labeling are assumed to be identical between global and phosphoproteomics datasets. Therefore, to account for sample-specific
biases in the phosphoproteome analysis, we applied the correction factors derived frommean-centering the global proteomics data.
Gene-wise Correlation Between Different Platforms
We calculated gene-wise correlations for each pair of the three platforms, including RNA-Seq, label-free proteomics, and TMT pro-
teomics. For each pair of the platforms, the analysis included the top 10% most variably expressed genes in each platform and
quantifiable in both platforms. Spearman’s correlation between the two platforms was calculated for each gene across all the
samples.
mRNA and Protein Correlation Across Datasets
We calculated average gene-wise RNA expression and performed the Pearson’s correlation coefficient analysis between the
prospective colon tumor samples (N = 106) and TCGA CRC samples (N = 90) (Zhang et al., 2014), TCGA breast tumor samples
(N = 1102, downloaded from TCGAbiolinks FPKM-UQ (Colaprico et al., 2016), TCGA ovarian tumor samples (N = 374, downloaded
from TCGAbiolinks FPKM-UQ), and colorectal cell lines (N = 44) (Wang et al., 2017b), respectively. Similarly, we calculated average
gene-wise protein expression (label-free) and performed the Pearson’s correlation coefficient analysis between the prospective
colon tumor samples (N = 100) and TCGA colorectal samples (N = 95) (Zhang et al., 2014), colorectal cell lines (N = 44) (Wang
et al., 2017b), and NCI-60 colorectal cell lines (N = 60, quantile-normalized) (Gholami et al., 2013), respectively.
Co-expression-based Gene Function Prediction
To compare the ability of different gene expression profiling datasets to predict gene function, we constructed k-nearest neighbor
co-expression networks as previously described (Wang et al., 2017a) using RNA-Seq, label-free proteomics, and TMT proteomics
data, respectively. Network-based gene function prediction was performed using the random walk-based network propagation
algorithm (Wang et al., 2017a). Prediction performance was evaluated using 5-fold cross validation for each KEGG pathway and
quantified based on the area under the receiver operating characteristic curve (AUROC).
Tumor versus Normal Differential Proteomic Analysis
TMT-based global proteomics data were used to perform differential proteome analysis between tumor and matched normal sam-
ples. Gene-level data were further filtered for non-missing values in at least 50% of samples. A pairedWilcoxon signed-rank test was
performed on overlapping samples to determine differential abundance of proteins between tumor and normal. Proteins with fold
change > 2 and Benjamini-Hochberg adjusted p-value < 0.01 were considered to be cancer-associated proteins. GO enrichment
analysis was performed usingWebGestalt (Wang et al., 2017c). For each cancer-associated protein, we checked immunohistochem-
istry images in colorectal tumors from the Human Protein Atlas (HPA, https://www.proteinatlas.org/), in which tumor-specific staining
is reported in four levels, i.e., high, medium, low, and not detected. Theweighted average score (IHC staining) was calculated for each
protein by assigning weight to high, medium, low, and not detected respectively.
Tumor versus Normal Differential Phosphoproteomic Analysis
Identified phosphopeptides were mapped to UniProt sequences (version July 2017), and named according to the canonical UniProt
sequence. If the peptide matchedmultiple canonical UniProt sequences, the best ID was chosen based on presence of the protein in
the proteomics data. If no canonical IDs had proteomics data, or if more than one protein was present in the quantified proteomics
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chosen. Peptides were filtered to those with an AscoreR 19 in at least one scan and a Q value < 0.01. Phosphorylation site levels
were determined by the median level for all peptides matching that site. Quantified sites and proteins were defined as those
containing non-missing values in at least 50% of the matched samples. Log fold change was calculated as the log2 peptide ratios
for normal samples subtracted from the log2 peptide ratios for tumor samples. Log fold change was correlated with log2 fold change
of protein abundance using Pearson correlation. Differential abundance was performed using the paired Wilcoxon signed-rank test.
Phosphorylation sites with fold change > 2 and Benjamini-Hochberg adjusted p-value < 0.01 were considered to be cancer-
associated phosphosites.
Kinase Activity Prediction
We predicted cancer-associated kinase activity based on two methods. First, sites annotated as activating kinase activity in Signor
(Lo Surdo et al., 2017) were used to predict kinase activity. Increased kinase activity was defined as significantly increased phosphor-
ylation on these sites (Benjamini-Hochberg adjusted p-value < 0.05,Wilcoxon signed-rank test) in tumor compared to matched adja-
cent normal. Sites with a protein abundance change greater than the phosphorylation abundance change were excluded. Second,
we performed phosphosite set enrichment analysis based on known kinase-target site relationships. Unique phosphorylation sites
were identified as a 13-mer sequence (±6 amino acids surrounding the phosphorylation site). Phosphorylation sites of kinases were
determined by a union of kinase-substrate interactions in PhosphoSitePlus (Hornbeck et al., 2015) and Signor. The median log2 fold
change of sites with at least 50% non-missing values was used to rank the phosphorylation sites and was submitted toWebGestaltR
for GSEA analysis. A minimum set size of 3 substrates and 1000 permutations were required.
Rb Phosphorylation Quantification and Correlation Analysis
Our phosphoproteomics data quantified six Rb phosphorylation sites with non-missing values in at least 50% of all samples,
including four sites (i.e., T373, S807, S811, and T826) that have been reported to directly or indirectly regulate E2F binding (Knudsen
and Wang, 1997; Rubin, 2013). We used the average of the four sites to quantify phospho-Rb abundance. Correlation between the
average Rb phosphorylation levels and other features was performed using Pearson’s correlation. Inferred activity was performed
using single sample GSEA implemented in the R package GSVA with a minimum gene set size of 10 (Ha¨nzelmann et al., 2013).
Phosphorylation sites of kinases were determined by a union of kinase-substrate interactions in PhosphoSitePlus and Signor. The
transcriptional targets of E2F transcription factors were collected from ENCODE Project Consortium (2011). Hallmark pathways
were collected from MSigDB (Liberzon et al., 2015). The tumor-normal protein levels were used to infer activity for E2F1 and the
apoptosis hallmark pathway. Although transcriptomic data for E2F1 targets would more directly reflect transcription factor activity,
RNA-Seq data were not available for the normal samples. The tumor-normal phosphorylation levels were used to infer CDK2 activity.
Cancer-testis Antigen Analysis
Cancer-testis (CT) antigens were downloaded from the CTdatabase (Almeida et al., 2009), which consists of 269 CT antigens with
carefully curated and annotated literature-derived information. The CT antigens that overlapped with the proteomics dataset were
used for further analysis.
Variant Peptide Identification
To identify variant peptides, we used a customized protein sequence database approach (Wang et al., 2012).We derived customized
protein sequence databases from bothmatched RNA-Seq andWXS data and then performed database searching using the custom-
ized databases for individual samples or individual TMT experiments. For label-free data, we built a customized database for each
individual sample based on germline and somatic variants fromWXS data and variants from RNA-Seq data. For TMT data, we built a
customized database for each TMT experiment based on germline and somatic variants fromWXS data and variants from RNA-Seq
data derived from corresponding tumor samples.We usedCustomprodbj (https://github.com/bzhanglab/customprodbj) for custom-
ized database construction. We used ANNOVAR (Wang et al., 2010) for variant annotation and dbSNP150, COSMIC83, dbnsfp33a
and Clinvar (version 20170905) were used. For variant peptide identification, MS/MS data were searched by three search engines
(MyriMatch version 2.2.10165, X!Tandem version Alanine 2017.02.01, and MS-GF+ version 2017.01.13) through IPeak against the
customized protein databases with decoy sequences. The results from the three search engines were then integrated by IPeak
and 1% FDR at PSM level was used. We further validated the identified variant peptides using PepQuery (http://www.pepquery.
org) (Wen et al., 2019) and only confidently identified variant peptides with PepQuery p value% 0.01 were retained.
MHC-binding Peptide Prediction
We used Optitype (Szolek et al., 2014) to perform human leukocyte antigen (HLA) genotyping for each sample based on WXS and
RNA-Seq data, respectively, and got exactly the same results. Then we used netMHCpan (Jurtz et al., 2017) to predict HLA-peptide
binding affinity for somatic mutation-derived variant peptides with a length between 8-11 amino acids. The HLA-peptides with IC50
binding affinity < 150 nM were considered to be neoantigens.e9 Cell 177, 1035–1049.e1–e11, May 2, 2019
Subtype Prediction
For proteomic subtype prediction, we performed row and column z-score transformation for the CPTAC-CRC and prospective colon
tumor samples separately. To assign prospective tumors to our previously identified proteomic subtypes (ProS A-E) (Zhang et al.,
2014), the R package pamr (https://cran.r-project.org/web/packages/pamr/index.html) was used to apply predefined signature
genes (Zhang et al., 2014) to the protein expression matrix. To identify the optimal value of the shrinkage parameter for our PAM pre-
diction model, we selected the value that minimized leave-one-out cross-validated misclassification error for the 79 CPTAC-CRC
tumor samples (error rate < 2%). We assigned 88 prospective tumors to the five proteomic subtypes with probability higher than 0.9.
For transcriptomic subtype prediction, we employed the random forest predictor implemented in the R package CMSclassifier
(https://github.com/Sage-Bionetworks/CMSclassifier) (Guinney et al., 2015) to assign the consensus molecular subtypes (CMSs)
to each sample based on the RSEM gene expression profiles from RNA-Seq. Using a default posterior probability of 0.5 as a
threshold for sample classification, we assigned 85 prospective tumors to the four CMS subtypes.
Unified View of Subtypes
The associations between the three subtype classifications (MSI, CMS and ProS) were assessed by the Fisher’s exact test. Only
subtype pairs with an adjusted p-value less than 0.05 were considered to be associated. An association network was constructed
based on the results, in which nodes represent the subtypes from individual classification systems, and weighted edges represent
statistically significant association between two subtypes and the level of significance. In this network, we found three disjoint
subnetworks or modules, which were defined as three unified multi-omics subtypes (UMSs). We further assigned each sample in
the cohort to the three UMS subtypes using a network centrality-based weighted voting algorithm described below.
Let V denote the vertices, E denote the edges and M denote the modules in the network. Ei,j represents the weight of the edge
connecting node i and j. We define
Eij =  log10Adj:Pði;jÞWhere Adj:P represents the adjusted p-value from the Fisher’sði;jÞ exact test between node i and node j, ci; j˛V.
Wi/m =
P
j˛m;< i;j >˛E;i < jEijP
j;k˛m;< j;k >˛E;j < kEjkWhere Wi/m represents the weighted contribution of node i (old subtypes) to the module m (new subtypes), ci˛V ;cm˛M. hi; ji
denotes the connection between node i and node j, ci; j˛V.
Finally, for each sample x,
Sx;m =
X
All i assigned to x
Wi/mSubtype=
8>><
>>:
m
0
; where Sx;m0 =maxðSx;mÞif
maxðSmÞP
Sm
> 0:7
}undecided}; if
maxðSmÞP
Sm
< 0:7WhereS represents the score of the UMS subtypem for a givenx;m sample x, andm’ represents the UMS assigned to the sample x. To
have amore definitive classification, we required a new subtype assignment to have a score greater than 70%of the sum of scores of
all three new subtypes.
Subtype-specific Marker Identification and Pathway Analysis
We performed both site-level phosphorylation and microRNA abundance comparisons across the different UMS subtypes using the
Wilcoxon rank sum test to identify subtype-specific markers. For phosphosite markers, we also required their subtype-specific
changes to be greater (or in a different direction) than changes at the protein level to highlight phosphorylation-level regulation.
To study metabolism differences between CMS3 and the other CMS subtypes, we downloaded the pre-defined metabolic gene
sets (Guinney et al., 2015) from the Synapse platform (https://www.synapse.org/#!Synapse:syn2623706/wiki/) and used ssGSEA
to infer RNA-based and protein-based pathway activities.
Quantification of Immune and Stromal Cell Infiltration
Overall immune infiltration, stromal infiltration and tumor purity reported in Table S1 were quantified by the ESTIMATE algorithm
(Yoshihara et al., 2013). In addition, individual immune cell abundance for the current cohort was inferred by the GSVA method
(Ha¨nzelmann et al., 2013) using a previously published immune cell signature gene panel (Angelova et al., 2015), which involves
33 different immune cell types.Cell 177, 1035–1049.e1–e11, May 2, 2019 e10
Metabolic Pathway Analysis
We performed both protein and mRNA abundance comparisons between the UMS MSI subtype and the other two UMS subtypes
using the Wilcoxon rank sum test. Mapping gene-level results to KEGG pathways (http://www.genome.jp/kegg) identified concor-
dant changes of enzymes involved in the glycolysis and oxidative phosphorylation pathways. To summarize sample-specific glyco-
lytic activities, we calculated the median of the gene-wise z-score-transformed protein abundance of all measured glycolytic genes.
SRM and PRISM-SRM Analysis
We performed targeted analysis of selected proteins, namely CD8A, SLC2A3, PKM1, and PKM2, in representative tumor samples
using selected reaction monitoring (SRM). For all proteins, analyses were performed on five MSI samples with relatively higher
estimated activated CD8 T cell levels (MSI/CD8-H) and five MSI samples with relatively lower estimated activated CD8 T cell levels
(MSI/CD8-L). For the analysis of SLC2A3, PKM1 and PKM2, we also included five samples from the CIN subtype and five from the
Mesenchymal subtype.
Proteotypic peptides selected for each target protein were synthesized as crude peptides with the C-terminal lysine or arginine
labeled with 13C/15N (New England Peptide, Gardner, MA) The heavy peptides were dissolved individually in 15% acetonitrile
(ACN) and 0.1% formic acid (FA) at a nominal concentration of 1.5 mM and mixed at a final concentration of 1 pmol/mL for each pep-
tide. The best transitions and optimal collision energy (CE) for each peptide were determined using a direct infusion experiment, and
3 transitions per peptide were selected after LC-SRM analysis of a colon tissue digest spikedwith the heavy peptides to confirm there
is no issue with peptide retention time, transition interference, and endogenous peptide detectability.
Reliable detection of CD8A required the use of the highly sensitive high-pressure, high-resolution separations coupled with intel-
ligent selection and multiplexing (PRISM)-SRM method (Shi et al., 2012). A nanoACQUITY UPLC system (Waters) equipped with a
reversed-phase capillary LC column (3-mmJupiter C18 bonded particles in-house packed in a 200 mm i.d. x 50 cmcapillary) was used
for the PRISM fractionation. Separations were performed at a flow rates of 2.2 mL/min using 10 mM ammonium formate (pH 10) in
water as mobile phase A and 10 mM ammonium formate (pH 10) in 90% ACN as mobile phase B. Forty five microliters of sample
with a peptide concentration of 1 mg/mL and 2 fmol/mL of heavy peptide standards was loaded onto the C18 capillary column and
separated using a 190-min gradient (min:%B): 35:1, 37:10, 52:15, 87:25, 112:35, 125:45, 150:90, 156:1. The eluent was automatically
deposited every minute onto a 96-well plate. Prior to peptide fraction collection, 20 mL of water was added to each well of the 96-well
plate to avoid potential loss of peptides and dilute the peptide fractions (1:10 dilution) so they can be directly analyzed using
LC-SRM (below).
Peptides from all the other target proteins in the colon tissue digests dissolved in 2% ACN/0.1% FA, as well as the CD8A PRISM
fractions, were analyzed by LC-SRM using a TSQ Vantage triple quadruple mass spectrometer (Thermo Fisher Scientific) equipped
with a nanoACQUITY UPLC system and an ACQUITY UPLC BEH 1.7-mm C18 100 mm i.d. x 10 cm column (Waters). The mobile
phases were (A) 0.1% FA in water and (B) 0.1% FA in ACN. Two microliter of 0.25 mg/mL colon digest sample with 5 fmol/mL heavy
peptides were loaded onto the column and separated at a flow rate of 400 nL/min using a 72-min gradient as follows (min:%B):
11:0.5, 13.5:10, 17:15, 38:25, 49:38, 50:95, 59:10, 60:95, 64:0.5. For PRISM fractions, 4 mL of each fraction were loaded onto the
column and separated with a 35-min gradient as follows (min:%B): 12:0.5, 13:10, 14:15, 20:25, 23:35, 25:95, 26:10, 27:95, 28:0.5.
The LC column is operated at a temperature of 44C. The parameters of the triple quadruple instrument were set to 0.7 fwhm Q1
resolution with 1 s cycle time. Data were acquired in time-scheduled SRM mode (retention time window: 10 min). For PRISM
fractions, data were acquired with unscheduled SRM mode.
All SRM data were analyzed using the Skyline software (MacLean et al., 2010). The total peak area ratios of endogenous light pep-
tides and their heavy isotope-labeled internal standards (i.e., L/H peak area ratios) were exported for quantitation. Peak detection and
integration were carried out according to two criteria: (1) same retention time and (2) similar L/H peaks area ratios for all transitions. All
data were also manually inspected to ensure correct retention time, peak detection and accurate integration. Peptides used in this
study were: SLC2A3 (QVTVLELFR), PKM1 (CLAAALIVLTESGR), PKM2 (IYVDDGLISLQVK), CD8A (TWNLGETVELK).
DATA AND SOFTWARE AVAILABILITY
Raw genomics data from this study are available at the Sequence Read Archive (SRA), BioProject ID: PRJNA514017 (ftp://ftp-trace.
ncbi.nlm.nih.gov/sra/review/SRP178677_20190114_143443_27e795eb0f314edf0479737480ab0f2a). Raw and low-level processed
proteomics data from this study are available at the CPTAC Data Portal (https://cptac-data-portal.georgetown.edu/cptac/s/S045).
All final data matrices are available at the LinkedOmics (Vasaikar et al., 2018) (http://linkedomics.org/cptac-colon/), which also
provides computational tools for further exploration of this dataset.e11 Cell 177, 1035–1049.e1–e11, May 2, 2019
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Figure S1. Data Quality Analysis, Related to Figure 1
(A–D) Average mRNA profile correlation between the prospective cohort (n = 106) and TCGA colorectal cohort (n = 90, A), TCGA breast cohort (n = 102, B), TCGA
ovarian cohort (n = 374, C), and colorectal cell lines (n = 44, D). (E-G) Average label-free protein profile correlation between the prospective cohort (n = 100) and
TCGA colorectal cohort (n = 95, E), colorectal cell lines (n = 44, F), and NCI-60 cell lines (n = 60, G). (H-I) Unsupervised principal component analysis (PCA) of the
TMT global (H) or phosphoproteomics (I) data. Samples analyzed in different TMT plex are shown with different shapes. Tumor and normal samples are shown in
different colors. Numbers in the parentheses are variance explained by PC1 and PC2. PCA was performed by metaX. (J-L) Distribution of gene-wise correlation
between label-free proteomics and RNA-Seq data (J), between TMT proteomics and RNA-Seq data (K), and between TMT and label-free data (L). For each
comparison, only genes quantifiable by both platforms and with the highest variances (top 10%) in either platforms were included in the analysis. (M-O) Scat-
terplots comparing the gene function prediction performance between co-expression networks derived from mRNA and label-free proteomics and RNA-Seq
data (M), from TMT proteomics and RNA-Seq data (N), and from TMT and label-free data (O). Network-based gene function prediction was performed using the
random walk-based network propagation algorithm for each KEGG pathway. Prediction performance was evaluated using 5-fold cross validation and quantified
on the basis of the area under the receiver operating characteristic curve (AUROC). Results for each KEGG pathway term is represented as a dot.
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Figure S2. Somatic Mutations and Microsatellite Instability, Related to Figure 2
(A) Mutation rates for individual tumor samples. Mutation rate was calculated on the basis of MuTect2 somatic single nucleotide variant (SNV) calls. (B) Numbers
of MuTect2 identified somatic INDELs for individual tumor samples. (C) Numbers of MSMuTect-Fisher identified somatic microsatellite INDELs (MS-INDELS)
for individual tumor samples. (D) Tumor samples classified based on microsatellite instability (MSI) status (MSI-H: red versus MSS: white) or mutation rate
(Hypermutated: red versus non-hypermutated: white). (E) Mutation spectrum for individual tumor samples. (F) Mutations in BRAF v600, mismatch repair genes,
POLE, and KRAS among all samples.
Figure S3. RB1 Mutation Frequency in Human Cancer, Related to Figure 4
The tumor suppressor gene RB1 is frequently mutated in retinoblastoma, bladder cancer, small cell lung cancer, and many other human cancers. However, it is
rarely mutated and is even amplified in colorectal cancer. Figure was generated using cBioPortal (http://www.cbioportal.org/).
Figure S4. Human Protein Atlas Immunohistochemistry Staining Data for the 31 Cancer-Associated Proteins, Related to Figure 5
(A) Proportions of colorectal tumors with high, medium, or low staining, or not detected (ND) as reported by HPA. (B) Representative IHC images for individual
proteins.
Figure S5. IGF2BP3 Protein Expression Data from Human Protein Atlas, Related to Figure 5
(A) IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) protein expression is restricted to fetal brain and reproductive organs such as testis, ovary,
and placenta. (B) Representative IHC images for IGF2BP3 in normal testis tissue (high), normal colon tissue (not detected), and colon cancer (high).
Figure S6. Colon Cancer-Subtype Analysis, Related to Figure 6
(A) Transcriptomic subtyping based on the consensus molecular subtypes (CMSs) and the RNA-seq data. (B) Proteomic subtyping based on previously
published proteomic subtypes and the label-free proteomics data. (C) Visualization of TMT data using the same sample and gene orders as in B. (D-F)
CMS3 has a vague molecular boundary. KRAS mutation is highlighted as a key characteristic of CMS3 in the original CMS paper (Guinney et al., 2015),
(legend continued on next page)
however, it was not enriched in the CMS3 subtype in our cohort (D). Upregulation of the metabolism-related pathways, another reported characteristic of
CMS3, was recapitulated to a certain extent in our cohort at the transcriptomic level (E); however, this pattern diminished when using proteomics data to
estimate pathway activities (F). (G) Comparison of chromosome instabilities across the three UMS subtypes. (H) Comparison of RB1 copy number
between the CIN subtype to other two UMS subtypes.
Figure S7. The Correlation between Glycolytic Activity and the Activated CD8 T Cell Level for Different Groups of Tumor Samples, Related to
Figure 7
(A) The whole cohort, (B) the MSI subtype, (C) the CIN subtype, and (D) the Mesenchymal subtype.
